Maia Pharms Inc patents expiration
1. Angiomax Rtu patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11903993 | MAIA PHARMS INC | Ready-to-use bivalirudin compositions |
May, 2039
(15 years from now) | |
| US11918622 | MAIA PHARMS INC | Ready-to-use bivalirudin compositions |
May, 2039
(15 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 25 July, 2019
Treatment: Use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci)
Dosage: SOLUTION;INTRAVENOUS
ANGIOMAX RTU family patents
2. Bortezomib patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
| US11752164 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma
Dosage: SOLUTION;INTRAVENOUS
BORTEZOMIB family patents
3. Sincalide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11737983 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11110063 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11318100 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
Drugs and Companies using SINCALIDE ingredient
Market Authorisation Date: 22 November, 2022
Treatment: Diagnosis of gall bladder disorders by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bi...
Dosage: POWDER;INTRAVENOUS
SINCALIDE family patents